Metastases kill patients, but disseminated cancers are resistant to therapies. The tumor biological events behind this are unknown due to lack of relevant model systems. Further, humans metabolize agents and present toxicities uniquely, hampering drug development. We have developed an all-human microphysiological system of the liver to study both tumor behavior in the common metastatic site, and drug metabolism/efficacy in the main metabolizing organ.
Also of special interest at this conference are presentations in the session on “Engineering Complex 3D Models of Tumor Microenvironment for Drug Screening and Functional Analysis,” which will cover topics such as tumor heterogeneity in bioengineered 3D models, 3D hydrogel co-cultures, and 3D ECM physiological systems. Also highly anticipated in the session on “Phenotypic Screening of 3D Models” is the talk by Dr. Aron Jaffe of Novartis Institutes for BioMedical Research who will present strategies for designing complex cellular assays for target discovery.
Writers and editors are invited to attend. To request a press pass, contact Lisa Scimemi, firstname.lastname@example.org.
Advanced registration discount deadline: October 10, 2014
Poster abstract submission deadline: October 10, 2014
For more details and to register, visit http://www.fastcongress.com/
About Cambridge Healthtech Institute
Cambridge Healthtech Institute (CHI), founded in 1992, is the industry leader in providing superior-quality scientific information to eminent researchers and business experts from top pharmaceutical, biotech, and academic organizations. Delivering an assortment of resources such as events, reports, publications and eNewsletters, CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett Educational Services, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Cambridge Healthtech Media Group, and The Knowledge Foundation.